
CORRIGENDUM**Remyelination researchers regroup after proof-of-concept setback in multiple sclerosis***Asher Mullard**Nature Reviews Drug Discovery* **15**, 519–521 (2016)

An RXR γ isoform-specific agonist was incorrectly identified as an RXR γ isoform-specific inhibitor. This has now been corrected online.